First Regular Session Seventy-fifth General Assembly STATE OF COLORADO

REVISED

This Version Includes All Amendments Adopted on Second Reading in the Second House

LLS NO. 25-0315.01 Jacob Baus x2173

HOUSE BILL 25-1063

HOUSE SPONSORSHIP

Hartsook and Brown, Bacon, Boesenecker, Camacho, Carter, Duran, Lindsay, McCormick, Phillips, Rutinel, Smith, Stewart R., Valdez, Woodrow, Zokaie

SENATE SPONSORSHIP

Michaelson Jenet,

House Committees

Health & Human Services

Senate Committees

Health & Human Services

A BILL FOR AN ACT

101	CONCERNING THE LAWFUL USE OF CRYSTALLINE POLYMORPH
102	PSILOCYBIN THAT IS APPROVED BY THE UNITED STATES FOOD
103	AND DRUG ADMINISTRATION.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at http://leg.colorado.gov.)

The bill makes a prescription medicine that contains crystalline polymorph psilocybin legal to prescribe, dispense, distribute, possess, use, and market in Colorado upon its approval by the United States food and drug administration.

SENATE nd Reading Unamended March 11, 2025

> HOUSE 3rd Reading Unamended January 23, 2025

HOUSE 2nd Reading Unamended January 22, 2025

1	Be it enacted by the General Assembly of the State of Colorado:
2	SECTION 1. Legislative declaration. (1) The general assembly
3	finds that:
4	(a) Treatment-resistant depression is defined by the federal food
5	and drug administration as depression that has failed to respond to 2 or
6	more medications of adequate dose and duration during a single
7	depressive episode;
8	(b) Serious public health implications are associated with
9	treatment-resistant depression, including a high cost of illness caused by
10	the need for higher intensity treatments, impaired psychosocial function,
11	a greater need for disability benefits, workplace absenteeism, negative
12	impact on caregivers, and increased suicidality;
13	(c) According to the largest study ever conducted on the
14	limitations of treating depression, treatment-resistant depression occurs
15	in approximately one-third of people treated for major depressive
16	disorder;
17	(d) Veterans are disproportionately likely to suffer from
18	treatment-resistant depression and other mental health conditions;
19	(e) According to a recent psychiatric journal publication,
20	approximately 68% of psychiatric clinic outpatient veterans satisfied
21	criteria for treatment-resistant depression;
22	(f) According to a recent medical journal publication,
23	approximately half of active-duty service members with post-traumatic
24	stress disorder also suffer from major depressive disorder, which is the
25	parent indication of treatment-resistant depression; and
26	(g) In clinical trials, crystalline polymorph psilocybin was shown

-2- 1063

to reduce depression scores significantly for patients with treatment-resistant depression when compared to active placebos.

- (2) Therefore, the general assembly declares that it is in the best interests of the people of Colorado that behavioral health professionals in Colorado have the ability to provide crystalline polymorph psilocybin to treat patients with treatment-resistant depression if the federal food and drug administration ultimately approves it for prescription use.
- 8 SECTION 2. In Colorado Revised Statutes, 18-18-203, amend 9 (2)(c)(XXI) as follows:
 - **18-18-203. Schedule I.** (2) Unless specifically excepted by Colorado or federal law or Colorado or federal regulation or more specifically included in another schedule, the following controlled substances are listed in schedule I:
 - (c) Any material, compound, mixture, or preparation containing any quantity of the following hallucinogenic substances, including any salts, isomers, and salts of isomers of them that are theoretically possible within the specific chemical designation:

(XXI) Psilocybin; EXCEPT THAT PSILOCYBIN DOES NOT INCLUDE A PRESCRIPTION DRUG PRODUCT CONTAINING CRYSTALLINE POLYMORPH PSILOCYBIN APPROVED BY THE FEDERAL FOOD AND DRUG ADMINISTRATION AND PLACED ON A SCHEDULE OF THE FEDERAL "CONTROLLED SUBSTANCES ACT", 21 U.S.C. SEC. 801 ET SEQ., OTHER THAN SCHEDULE I, OR EXEMPT FROM ONE OR MORE PROVISIONS OF THAT ACT, AND THAT IS INTENDED FOR PRESCRIBED USE AND DISPENSED BY A PHARMACY OR PRESCRIPTION DRUG OUTLET REGISTERED BY THE STATE OF COLORADO AND ONLY POSSESSED BY A PERSON AUTHORIZED TO POSSESS A CONTROLLED SUBSTANCE PURSUANT TO SECTION 18-18-302. ANY PRESCRIPTION DRUG PRODUCT

-3- 1063

1	CONTAINING CRYSTALLINE POLYMORPH PSILOCYBIN THAT IS APPROVED BY
2	THE FEDERAL FOOD AND DRUG ADMINISTRATION MUST BE CONTROLLED IN
3	COLORADO IN THE SAME MANNER AS REQUIRED BY ANY FEDERAL
4	CONTROL DESIGNATION PURSUANT TO THE FEDERAL "CONTROLLED
5	SUBSTANCES ACT", OR ANY EXEMPTION FROM ONE OR MORE PROVISIONS
6	OF THAT ACT; AND IS SUBJECT TO THE PROVISIONS SET FORTH IN PART 1 OF
7	ARTICLE 280 OF TITLE 12 AND PART 3 OF THIS ARTICLE 18. NOTHING IN
8	THIS SUBSECTION $(2)(c)(XXI)$ EXEMPTS A PERSON FROM ANY VIOLATION
9	OF PART 4 OF THIS ARTICLE 18.
10	SECTION 3. Act subject to petition - effective date. This act
10 11	SECTION 3. Act subject to petition - effective date. This act takes effect at 12:01 a.m. on the day following the expiration of the
	• •
11	takes effect at 12:01 a.m. on the day following the expiration of the
11 12	takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly; except
11 12 13	takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly; except that, if a referendum petition is filed pursuant to section 1 (3) of article V
11 12 13 14	takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly; except that, if a referendum petition is filed pursuant to section 1 (3) of article V of the state constitution against this act or an item, section, or part of this
11 12 13 14 15	takes effect at 12:01 a.m. on the day following the expiration of the ninety-day period after final adjournment of the general assembly; except that, if a referendum petition is filed pursuant to section 1 (3) of article V of the state constitution against this act or an item, section, or part of this act within such period, then the act, item, section, or part will not take

-4- 1063